Announcements Trials
Browse Landscape

Phase

Phase 3 3

Status

Recruiting 2Completed 1

Sponsor Class

OTHER 3INDUSTRY 3

Study Type

Interventional 3

Sponsor

Conditions

Myasthenia Gravis 3Muscle Weakness 1Autoimmune Diseases 1

Interventions

pembrolizumab 1023Carboplatin 964Paclitaxel 933Gemcitabine 794Cisplatin 751Docetaxel 683Bevacizumab 609Pemetrexed 502Nivolumab 487Cyclophosphamide 471Capecitabine 461Fluorouracil 418Dexamethasone 403Rituximab 372Oxaliplatin 348Injections 345atezolizumab 298Trastuzumab 298Leucovorin 288Cetuximab 282Irinotecan 268130-nm albumin-bound paclitaxel 254Prednisone 245Doxorubicin 240Ipilimumab 226Lenalidomide 220fludarabine 218Fulvestrant 217durvalumab 205Erlotinib Hydrochloride 188

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
INDUSTRY × Interventional × telitacicept × Clear all
NCT06456580 2026-05-07

A Study of Telitacicept for the Treatment of Generalized Myasthenia Gravis (UPSTREAM MG)

Vor Biopharma

Phase 3 Recruiting
180 enrolled

Myasthenia Gravis

NCT07249632 2026-04-09

A Study of Telitacicept in Patients With Ocular Myasthenia Gravis (OMG)

RemeGen Co., Ltd.

Phase 3 Recruiting
120 enrolled

Myasthenia Gravis

NCT05737160 2025-05-23

Study of Telitacicept in Generalized Myasthenia Gravis

RemeGen Co., Ltd.

Phase 3 Completed
114 enrolled

Autoimmune Diseases, Myasthenia Gravis, Muscle Weakness

Data powered by HemOnc (CC BY 4.0) Colophon âš¡